title: Update on antiphospholipid antibodies.
abstract: The association of antibodies with an apparent specificity for anionic phospholipids with thrombosis, fetal loss, thrombocytopenia, and certain other clinical manifestations is now well-recognized as the antiphospholipid syndrome (APS). Recent advances in our understanding of the antibodies and antigens involved include discovery of the crystal structure of beta2-glycoprotein I, (beta2GPI), genetic studies of beta2GPI polymorphisms, and the development of anti-beta2GPI and antiprothrombin immunoassays as clinical laboratory tests. The identification of antigen-specific T cells in APS patients has stimulated interest in the role of the cellular immune response in the syndrome. Clinical research in APS will also benefit from the development of preliminary classification criteria.
authors.affiliation: Division of Rheumatology & Immunology, University of North Carolina at Chapel Hill, 27599-7280, USA. roubey@med.unc.edu
authors.forename: R A
authors.initials: RA
authors.lastname: Roubey
mesh_terms: D017304:Annexin A5 / Q000502:physiology; D017152:Antibodies, Antiphospholipid / Q000097:blood / Q000276:immunology*; D000925:Anticoagulants / Q000008:administration & dosage / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D001323:Autoantibodies; D002493:Central Nervous System Diseases / Q000209:etiology; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D011516:Prothrombin / Q000276:immunology; D013927:Thrombosis / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D014859:Warfarin / Q000008:administration & dosage; D053482:beta 2-Glycoprotein I
chemical_list: D017304:Annexin A5; D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D001323:Autoantibodies; D006023:Glycoproteins; D053482:beta 2-Glycoprotein I; D014859:Warfarin; D011516:Prothrombin